Targeted Therapies in Epithelial Ovarian Cancer
AbstractMolecularly targeted therapy is relatively new to ovarian cancer despite the unquestionable success with these agents in other solid tumours such as breast and colorectal cancer. Advanced ovarian cancer is chemosensitive and patients can survive several years on treatment. However chemotherapy diminishes in efficacy over time whilst toxicities persist. Newer biological agents that target explicit molecular pathways and lack specific chemotherapy toxicities such as myelosuppression offer the advantage of long-term therapy with a manageable toxicity profile enabling patients to enjoy a good quality of life. In this review we appraise the emerging data on novel targeted therapies in ovarian cancer. We discuss the role of these compounds in the front-line treatment of ovarian cancer and in relapsed disease; and describe how the development of predictive clinical, molecular and imaging biomarkers will define the role of biological agents in the treatment of ovarian cancer. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Dean, E.; El-Helw, L.; Hasan, J. Targeted Therapies in Epithelial Ovarian Cancer. Cancers 2010, 2, 88-113.
Dean E, El-Helw L, Hasan J. Targeted Therapies in Epithelial Ovarian Cancer. Cancers. 2010; 2(1):88-113.Chicago/Turabian Style
Dean, Emma; El-Helw, Loaie; Hasan, Jurjees. 2010. "Targeted Therapies in Epithelial Ovarian Cancer." Cancers 2, no. 1: 88-113.